Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 23, 2000
Business Overview: The Company operates two primary segments: Healthcare Distribution (Dental, Medical, Veterinary, and International) and Technology (practice management software). The Company distributes healthcare products and services to office-based practitioners globally.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 23, 2000 |
Nine Months Ended Sep 23, 2000 |
|---|---|---|
| Net Sales | $603,037 | $1,725,021 |
| Gross Profit | $185,110 | $537,045 |
| Gross Margin | 30.7% | 31.1% |
| Operating Income | $28,944 | $83,403 |
| Net Income | $16,238 | $44,017 |
| Diluted EPS | $0.39 | $1.06 |
| Cash from Operations (9mo) | $85,105 | |
| Cash & Equivalents (End of Period) | $37,242 | |
| Total Debt (Current + Long-term) | $305,781 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.2% ($24.2 million) for the quarter and 3.0% ($50.6 million) for the nine months compared to the prior year periods.
- Segment Performance:
- Medical: Strong growth of 12.3% (quarter) and 8.9% (nine months) driven by core physician office sales.
- Dental: Increased 2.2% (quarter) and 1.6% (nine months) due to improved equipment sales.
- International: Decreased 6.8% (quarter) and 3.9% (nine months) primarily due to unfavorable foreign exchange rates, which reduced sales by $12.6 million and $30.6 million respectively.
- Profitability: Gross profit margins improved to 30.7% (quarter) and 31.1% (nine months) from 30.1% and 30.5% in the prior year, driven by sales mix changes.
- Restructuring Costs: The Company incurred $5.4 million in one-time restructuring costs in the third quarter of 2000 (compared to $0 in the prior year quarter) related to a plan to eliminate approximately 300 positions.
- Merger Costs: Merger and integration costs were minimal in 2000 ($585k for nine months) compared to $13.5 million in the prior year period.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects to incur an additional $8.6 million in restructuring costs in the fourth quarter of 2000. The plan is projected to yield annual pre-tax savings of approximately $20.0 million.
- Subsequent Event: On October 23, 2000, the Company sold its 50% interest in HS Pharmaceutical. A non-recurring loss of approximately $0.05 per share is expected in the fourth quarter.
- Liquidity: The Company maintains a $150.0 million revolving credit facility (with $15.1 million borrowed) and $130.0 million in Senior Notes due 2009. Management believes existing cash flows and credit facilities are sufficient for short and long-term needs.
- Legal Proceedings: The Company is a defendant in approximately 76 product liability cases, including 59 involving latex glove allergies and 9 involving "Phen/fen" drugs. A class action lawsuit regarding practice management software (Easy Dental) was certified by the Texas Court of Appeals; the Company plans to appeal to the Texas Supreme Court.
- Market Risks: Risks include foreign currency fluctuations, consolidation of healthcare practitioners, and the impact of e-commerce competition.
Investor Verification Checklist
- Verify the impact of the $8.6 million expected fourth-quarter restructuring costs on full-year earnings.
- Confirm the magnitude of the non-recurring loss from the HS Pharmaceutical divestiture in the upcoming quarter.
- Monitor the status of the Easy Dental class action lawsuit and potential indemnification from manufacturers in product liability cases.
- Assess the sustainability of the Medical segment's growth rate (12.3% quarterly) versus the decline in International sales due to currency headwinds.
- Review the Company's ability to achieve the projected $20.0 million in annual pre-tax savings from the restructuring plan.